There are currently 16 active clinical trials seeking participants for Acute Ischemic Stroke research studies. The states with the highest number of trials for Acute Ischemic Stroke participants are Shandong, California, Henan and Beijing.
Safety Study of PP-007 in Subjects With Acute Ischemic Stroke
NCT04677777
Recruiting
The HEMERA-1 Extension (Part III) is a prospective, open-label, multicenter study to evaluate safety of two doses of PP-007 in Acute Ischemic Stroke (AIS) subjects receiving Intravenous Thrombolysis (IVT) or mechanical thrombectomy (MT) or IVT+MT as standard of care (SOC). Subjects will receive two doses of PP-007 infusion 24 ± 6 hours apart in addition to the site-specific SOC protocol. PP-007 is PEGylated bovine carboxyhemoglobin and will be administered via IV infusion. The effects on collate... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/28/2024
Locations: Baptist Health Research Institute, Jacksonville, Florida +7 locations
Conditions: Acute Ischemic Stroke
Register for Updates
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
NCT05390580
Recruiting
This is a randomized open-label, with blinded outcome pilot study to evaluate the effect on inflammatory laboratory values and explore clinical outcomes in patients who present with ischemic strokes due to large vessel occlusions and are treated with either current accepted management, or accepted management in addition to transcutaneous auricular vagal nerve stimulation.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
12/05/2023
Locations: Washington University in St. Louis School of Medicine, Saint Louis, Missouri
Conditions: Acute Ischemic Stroke
Register for Updates
Hyperbaric Oxygen Therapy in Acute Ischemic Stroke Ischemic Stroke Recovery (Pro00061930)
NCT06148285
Recruiting
This study will critically examine the feasibility, safety and efficacy of HBOT during inpatient rehabilitation (IPR) after acute ischemic stroke measured by non-disruption of 3 hours of daily therapy, frequency of neurological deterioration or complications (seizure, hemorrhage, brain edema), and functional communication, activities of daily living (ADLs) and mobility.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2023
Locations: Touro Infirmary New Orleans, New Orleans, Louisiana
Conditions: Acute Ischemic Stroke
Register for Updates
Single Ascending Dose Safety and Tolerability of NTS-104 Healthy Adults
NCT05547438
Recruiting
NTS-104 TRIS will be administered as a single intravenous dose to healthy subjects at doses of 0.8, 4, 8 and 16 mg/kg in 4 Cohorts. Each cohort of 8 subjects will begin with dosing 2 sentinel subjects with one being given the investigational product and one the placebo. If no safety issues arise, dosing the remaining subjects in the cohort will begin. A Safety Review Committee will review the safety and pharmacokinetic data before approving escalation to the next dose level.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/24/2023
Locations: Parexel International EPCU Baltimore 7th floor, Baltimore, Maryland
Conditions: Acute Ischemic Stroke
Register for Updates